185 related articles for article (PubMed ID: 26335014)
1. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Vaz J; Ansari D; Sasor A; Andersson R
Pancreas; 2015 Oct; 44(7):1024-35. PubMed ID: 26335014
[TBL] [Abstract][Full Text] [Related]
2. SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer.
Ramu I; Buchholz SM; Patzak MS; Goetze RG; Singh SK; Richards FM; Jodrell DI; Sipos B; Ströbel P; Ellenrieder V; Hessmann E; Neesse A
EBioMedicine; 2019 Oct; 48():161-168. PubMed ID: 31597597
[TBL] [Abstract][Full Text] [Related]
3. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Sinn M; Sinn BV; Striefler JK; Lindner JL; Stieler JM; Lohneis P; Bischoff S; Bläker H; Pelzer U; Bahra M; Dietel M; Dörken B; Oettle H; Riess H; Denkert C
Ann Oncol; 2014 May; 25(5):1025-32. PubMed ID: 24562449
[TBL] [Abstract][Full Text] [Related]
4. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Hidalgo M; Plaza C; Musteanu M; Illei P; Brachmann CB; Heise C; Pierce D; Lopez-Casas PP; Menendez C; Tabernero J; Romano A; Wei X; Lopez-Rios F; Von Hoff DD
Clin Cancer Res; 2015 Nov; 21(21):4811-8. PubMed ID: 26169969
[TBL] [Abstract][Full Text] [Related]
5. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Shintakuya R; Kondo N; Murakami Y; Uemura K; Nakagawa N; Okano K; Takahashi S; Sueda T
Pancreatology; 2018 Mar; 18(2):191-197. PubMed ID: 29295776
[TBL] [Abstract][Full Text] [Related]
6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
7. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
[TBL] [Abstract][Full Text] [Related]
8. Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma.
Toyota K; Murakami Y; Kondo N; Uemura K; Nakagawa N; Takahashi S; Sueda T
J Gastrointest Surg; 2017 Jun; 21(6):990-999. PubMed ID: 28342122
[TBL] [Abstract][Full Text] [Related]
9. The 'SPARC' of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review).
Rossi MK; Gnanamony M; Gondi CS
Int J Oncol; 2016 May; 48(5):1765-71. PubMed ID: 26983777
[TBL] [Abstract][Full Text] [Related]
10. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
[TBL] [Abstract][Full Text] [Related]
11. Stromal expression of SPARC in pancreatic adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
[TBL] [Abstract][Full Text] [Related]
12. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
[TBL] [Abstract][Full Text] [Related]
13. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Liang C; Shi S; Meng Q; Liang D; Ji S; Zhang B; Qin Y; Xu J; Ni Q; Yu X
Cell Mol Life Sci; 2018 Mar; 75(6):1001-1012. PubMed ID: 28993833
[TBL] [Abstract][Full Text] [Related]
14. [New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Huguet F; Fernet M; Monnier L; Touboul E; Favaudon V
Cancer Radiother; 2011 Aug; 15(5):365-75. PubMed ID: 21664851
[TBL] [Abstract][Full Text] [Related]
15. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
[TBL] [Abstract][Full Text] [Related]
16. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
17. SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.
Arqueros C; Salazar J; Arranz MJ; Sebio A; Mora J; Sullivan I; Tobeña M; Martín-Richard M; Barnadas A; Baiget M; Páez D
Med Oncol; 2017 Aug; 34(8):136. PubMed ID: 28687963
[TBL] [Abstract][Full Text] [Related]
18. SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.
Kaleağasıoğlu F; Berger MR
World J Gastroenterol; 2014 Oct; 20(40):14747-59. PubMed ID: 25356037
[TBL] [Abstract][Full Text] [Related]
19. Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.
Whatcott CJ; Han H; Von Hoff DD
Cancer J; 2015; 21(4):299-306. PubMed ID: 26222082
[TBL] [Abstract][Full Text] [Related]
20. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients.
Miyoshi K; Sato N; Ohuchida K; Mizumoto K; Tanaka M
Anticancer Res; 2010 Mar; 30(3):867-71. PubMed ID: 20393008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]